SARS CTL vaccine candidates; HLA supertype‐, genome‐wide scanning and biochemical validation
Identifieur interne : 005711 ( Main/Exploration ); précédent : 005710; suivant : 005712SARS CTL vaccine candidates; HLA supertype‐, genome‐wide scanning and biochemical validation
Auteurs : C. Sylvester-Hvid [Danemark] ; M. Nielsen [Danemark] ; K. Lamberth [Danemark] ; G. R Der [Danemark] ; S. Justesen [Danemark] ; C. Lundegaard [Danemark] ; P. Worning [Danemark] ; H. Thomadsen [Danemark] ; O. Lund [Danemark] ; S. Brunak [Danemark] ; S. Buus [Danemark]Source :
- Tissue Antigens [ 0001-2815 ] ; 2004-05.
Descripteurs français
- KwdFr :
- Antigène HLA-A3 (immunologie), Antigènes HLA (immunologie), Antigènes HLA-A (immunologie), Biologie informatique, Déterminants antigéniques des lymphocytes T (immunologie), Génome viral, Humains, Liaison aux protéines, Peptides (immunologie), Présentation d'antigène, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (isolement et purification).
- MESH :
- génétique : Virus du SRAS.
- immunologie : Antigène HLA-A3, Antigènes HLA, Antigènes HLA-A, Déterminants antigéniques des lymphocytes T, Peptides, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- isolement et purification : Virus du SRAS.
- Biologie informatique, Génome viral, Humains, Liaison aux protéines, Présentation d'antigène, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Antigen Presentation, Computational Biology, Epitopes, T-Lymphocyte (immunology), Genome, Viral, HLA Antigens (immunology), HLA-A Antigens (immunology), HLA-A3 Antigen (immunology), Humans, Neural Networks, Computer, Peptides (immunology), Protein Binding, SARS Virus (genetics), SARS Virus (immunology), SARS Virus (isolation & purification), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (therapy), Viral Vaccines (immunology).
- MESH :
- chemical , immunology : Epitopes, T-Lymphocyte, HLA Antigens, HLA-A Antigens, HLA-A3 Antigen, Peptides, Viral Vaccines.
- genetics : SARS Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- isolation & purification : SARS Virus.
- therapy : Severe Acute Respiratory Syndrome.
- Antigen Presentation, Computational Biology, Genome, Viral, Humans, Neural Networks, Computer, Protein Binding.
Abstract
Abstract: An effective Severe Acute Respiratory Syndrome (SARS) vaccine is likely to include components that can induce specific cytotoxic T‐lymphocyte (CTL) responses. The specificities of such responses are governed by human leukocyte antigen (HLA)‐restricted presentation of SARS‐derived peptide epitopes. Exact knowledge of how the immune system handles protein antigens would allow for the identification of such linear sequences directly from genomic/proteomic sequence information (Lauemoller et al., Rev Immunogenet 2001: 2: 477–91). The latter was recently established when a causative coronavirus (SARS‐CoV) was isolated and full‐length sequenced (Marra et al., Science 2003: 300: 1399–404). Here, we have combined advanced bioinformatics and high‐throughput immunology to perform an HLA supertype‐, genome‐wide scan for SARS‐specific CTL epitopes. The scan includes all nine human HLA supertypes in total covering >99% of all individuals of all major human populations (Sette & Sidney, Immunogenetics 1999: 50: 201–12). For each HLA supertype, we have selected the 15 top candidates for test in biochemical binding assays. At this time (approximately 6 months after the genome was established), we have tested the majority of the HLA supertypes and identified almost 100 potential vaccine candidates. These should be further validated in SARS survivors and used for vaccine formulation. We suggest that immunobioinformatics may become a fast and valuable tool in rational vaccine design.
Url:
- https://api.istex.fr/ark:/67375/WNG-4B4MX42W-J/fulltext.pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161580
DOI: 10.1111/j.0001-2815.2004.00221.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000302
- to stream Istex, to step Curation: 000302
- to stream Istex, to step Checkpoint: 001D89
- to stream Pmc, to step Corpus: 001499
- to stream Pmc, to step Curation: 001499
- to stream Pmc, to step Checkpoint: 001533
- to stream PubMed, to step Corpus: 002E39
- to stream PubMed, to step Curation: 002E39
- to stream PubMed, to step Checkpoint: 002A99
- to stream Ncbi, to step Merge: 000766
- to stream Ncbi, to step Curation: 000766
- to stream Ncbi, to step Checkpoint: 000766
- to stream Main, to step Merge: 005B57
- to stream Main, to step Curation: 005711
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS CTL vaccine candidates; HLA supertype‐, genome‐wide scanning and biochemical validation</title><author><name sortKey="Sylvester Vid, C" sort="Sylvester Vid, C" uniqKey="Sylvester Vid C" first="C." last="Sylvester-Hvid">C. Sylvester-Hvid</name></author><author><name sortKey="Nielsen, M" sort="Nielsen, M" uniqKey="Nielsen M" first="M." last="Nielsen">M. Nielsen</name></author><author><name sortKey="Lamberth, K" sort="Lamberth, K" uniqKey="Lamberth K" first="K." last="Lamberth">K. Lamberth</name></author><author><name sortKey="R Der, G" sort="R Der, G" uniqKey="R Der G" first="G." last="R Der">G. R Der</name></author><author><name sortKey="Justesen, S" sort="Justesen, S" uniqKey="Justesen S" first="S." last="Justesen">S. Justesen</name></author><author><name sortKey="Lundegaard, C" sort="Lundegaard, C" uniqKey="Lundegaard C" first="C." last="Lundegaard">C. Lundegaard</name></author><author><name sortKey="Worning, P" sort="Worning, P" uniqKey="Worning P" first="P." last="Worning">P. Worning</name></author><author><name sortKey="Thomadsen, H" sort="Thomadsen, H" uniqKey="Thomadsen H" first="H." last="Thomadsen">H. Thomadsen</name></author><author><name sortKey="Lund, O" sort="Lund, O" uniqKey="Lund O" first="O." last="Lund">O. Lund</name></author><author><name sortKey="Brunak, S" sort="Brunak, S" uniqKey="Brunak S" first="S." last="Brunak">S. Brunak</name></author><author><name sortKey="Buus, S" sort="Buus, S" uniqKey="Buus S" first="S." last="Buus">S. Buus</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8A3B5C6659F9727960EFE6E4405375EC6436E8C9</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.0001-2815.2004.00221.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-4B4MX42W-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000302</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000302</idno><idno type="wicri:Area/Istex/Curation">000302</idno><idno type="wicri:Area/Istex/Checkpoint">001D89</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D89</idno><idno type="wicri:doubleKey">0001-2815:2004:Sylvester Vid C:sars:ctl:vaccine</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161580</idno><idno type="RBID">PMC:7161580</idno><idno type="wicri:Area/Pmc/Corpus">001499</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001499</idno><idno type="wicri:Area/Pmc/Curation">001499</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001499</idno><idno type="wicri:Area/Pmc/Checkpoint">001533</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001533</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15104671</idno><idno type="wicri:Area/PubMed/Corpus">002E39</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E39</idno><idno type="wicri:Area/PubMed/Curation">002E39</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E39</idno><idno type="wicri:Area/PubMed/Checkpoint">002A99</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A99</idno><idno type="wicri:Area/Ncbi/Merge">000766</idno><idno type="wicri:Area/Ncbi/Curation">000766</idno><idno type="wicri:Area/Ncbi/Checkpoint">000766</idno><idno type="wicri:doubleKey">0001-2815:2004:Sylvester Vid C:sars:ctl:vaccine</idno><idno type="wicri:Area/Main/Merge">005B57</idno><idno type="wicri:Area/Main/Curation">005711</idno><idno type="wicri:Area/Main/Exploration">005711</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">SARS CTL vaccine candidates; HLA supertype‐, genome‐wide scanning and biochemical validation</title><author><name sortKey="Sylvester Vid, C" sort="Sylvester Vid, C" uniqKey="Sylvester Vid C" first="C." last="Sylvester-Hvid">C. Sylvester-Hvid</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Division of Experimental Immunology, Institute of Medical Microbiology and Immunology (IMMI), University of Copenhagen, Copenhagen N</wicri:regionArea><wicri:noRegion>Copenhagen N</wicri:noRegion></affiliation></author><author><name sortKey="Nielsen, M" sort="Nielsen, M" uniqKey="Nielsen M" first="M." last="Nielsen">M. Nielsen</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Center for Biological Sequence Analysis (CBS), Technical University of Denmark, Lyngby</wicri:regionArea><wicri:noRegion>Lyngby</wicri:noRegion></affiliation></author><author><name sortKey="Lamberth, K" sort="Lamberth, K" uniqKey="Lamberth K" first="K." last="Lamberth">K. Lamberth</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Division of Experimental Immunology, Institute of Medical Microbiology and Immunology (IMMI), University of Copenhagen, Copenhagen N</wicri:regionArea><wicri:noRegion>Copenhagen N</wicri:noRegion></affiliation></author><author><name sortKey="R Der, G" sort="R Der, G" uniqKey="R Der G" first="G." last="R Der">G. R Der</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Division of Experimental Immunology, Institute of Medical Microbiology and Immunology (IMMI), University of Copenhagen, Copenhagen N</wicri:regionArea><wicri:noRegion>Copenhagen N</wicri:noRegion></affiliation></author><author><name sortKey="Justesen, S" sort="Justesen, S" uniqKey="Justesen S" first="S." last="Justesen">S. Justesen</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Division of Experimental Immunology, Institute of Medical Microbiology and Immunology (IMMI), University of Copenhagen, Copenhagen N</wicri:regionArea><wicri:noRegion>Copenhagen N</wicri:noRegion></affiliation></author><author><name sortKey="Lundegaard, C" sort="Lundegaard, C" uniqKey="Lundegaard C" first="C." last="Lundegaard">C. Lundegaard</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Center for Biological Sequence Analysis (CBS), Technical University of Denmark, Lyngby</wicri:regionArea><wicri:noRegion>Lyngby</wicri:noRegion></affiliation></author><author><name sortKey="Worning, P" sort="Worning, P" uniqKey="Worning P" first="P." last="Worning">P. Worning</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Center for Biological Sequence Analysis (CBS), Technical University of Denmark, Lyngby</wicri:regionArea><wicri:noRegion>Lyngby</wicri:noRegion></affiliation></author><author><name sortKey="Thomadsen, H" sort="Thomadsen, H" uniqKey="Thomadsen H" first="H." last="Thomadsen">H. Thomadsen</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Division of Experimental Immunology, Institute of Medical Microbiology and Immunology (IMMI), University of Copenhagen, Copenhagen N</wicri:regionArea><wicri:noRegion>Copenhagen N</wicri:noRegion></affiliation></author><author><name sortKey="Lund, O" sort="Lund, O" uniqKey="Lund O" first="O." last="Lund">O. Lund</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Center for Biological Sequence Analysis (CBS), Technical University of Denmark, Lyngby</wicri:regionArea><wicri:noRegion>Lyngby</wicri:noRegion></affiliation></author><author><name sortKey="Brunak, S" sort="Brunak, S" uniqKey="Brunak S" first="S." last="Brunak">S. Brunak</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Center for Biological Sequence Analysis (CBS), Technical University of Denmark, Lyngby</wicri:regionArea><wicri:noRegion>Lyngby</wicri:noRegion></affiliation></author><author><name sortKey="Buus, S" sort="Buus, S" uniqKey="Buus S" first="S." last="Buus">S. Buus</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Division of Experimental Immunology, Institute of Medical Microbiology and Immunology (IMMI), University of Copenhagen, Copenhagen N</wicri:regionArea><wicri:noRegion>Copenhagen N</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Danemark</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Tissue Antigens</title><title level="j" type="alt">TISSUE ANTIGENS</title><idno type="ISSN">0001-2815</idno><idno type="eISSN">1399-0039</idno><imprint><biblScope unit="vol">63</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="395">395</biblScope><biblScope unit="page" to="400">400</biblScope><biblScope unit="page-count">6</biblScope><publisher>Munksgaard International Publishers</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-05">2004-05</date></imprint><idno type="ISSN">0001-2815</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-2815</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigen Presentation</term><term>Computational Biology</term><term>Epitopes, T-Lymphocyte (immunology)</term><term>Genome, Viral</term><term>HLA Antigens (immunology)</term><term>HLA-A Antigens (immunology)</term><term>HLA-A3 Antigen (immunology)</term><term>Humans</term><term>Neural Networks, Computer</term><term>Peptides (immunology)</term><term>Protein Binding</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (isolation & purification)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antigène HLA-A3 (immunologie)</term><term>Antigènes HLA (immunologie)</term><term>Antigènes HLA-A (immunologie)</term><term>Biologie informatique</term><term>Déterminants antigéniques des lymphocytes T (immunologie)</term><term>Génome viral</term><term>Humains</term><term>Liaison aux protéines</term><term>Peptides (immunologie)</term><term>Présentation d'antigène</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes, T-Lymphocyte</term><term>HLA Antigens</term><term>HLA-A Antigens</term><term>HLA-A3 Antigen</term><term>Peptides</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigène HLA-A3</term><term>Antigènes HLA</term><term>Antigènes HLA-A</term><term>Déterminants antigéniques des lymphocytes T</term><term>Peptides</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antigen Presentation</term><term>Computational Biology</term><term>Genome, Viral</term><term>Humans</term><term>Neural Networks, Computer</term><term>Protein Binding</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Biologie informatique</term><term>Génome viral</term><term>Humains</term><term>Liaison aux protéines</term><term>Présentation d'antigène</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: An effective Severe Acute Respiratory Syndrome (SARS) vaccine is likely to include components that can induce specific cytotoxic T‐lymphocyte (CTL) responses. The specificities of such responses are governed by human leukocyte antigen (HLA)‐restricted presentation of SARS‐derived peptide epitopes. Exact knowledge of how the immune system handles protein antigens would allow for the identification of such linear sequences directly from genomic/proteomic sequence information (Lauemoller et al., Rev Immunogenet 2001: 2: 477–91). The latter was recently established when a causative coronavirus (SARS‐CoV) was isolated and full‐length sequenced (Marra et al., Science 2003: 300: 1399–404). Here, we have combined advanced bioinformatics and high‐throughput immunology to perform an HLA supertype‐, genome‐wide scan for SARS‐specific CTL epitopes. The scan includes all nine human HLA supertypes in total covering >99% of all individuals of all major human populations (Sette & Sidney, Immunogenetics 1999: 50: 201–12). For each HLA supertype, we have selected the 15 top candidates for test in biochemical binding assays. At this time (approximately 6 months after the genome was established), we have tested the majority of the HLA supertypes and identified almost 100 potential vaccine candidates. These should be further validated in SARS survivors and used for vaccine formulation. We suggest that immunobioinformatics may become a fast and valuable tool in rational vaccine design.</div></front></TEI><affiliations><list><country><li>Danemark</li></country></list><tree><country name="Danemark"><noRegion><name sortKey="Sylvester Vid, C" sort="Sylvester Vid, C" uniqKey="Sylvester Vid C" first="C." last="Sylvester-Hvid">C. Sylvester-Hvid</name></noRegion><name sortKey="Brunak, S" sort="Brunak, S" uniqKey="Brunak S" first="S." last="Brunak">S. Brunak</name><name sortKey="Buus, S" sort="Buus, S" uniqKey="Buus S" first="S." last="Buus">S. Buus</name><name sortKey="Buus, S" sort="Buus, S" uniqKey="Buus S" first="S." last="Buus">S. Buus</name><name sortKey="Justesen, S" sort="Justesen, S" uniqKey="Justesen S" first="S." last="Justesen">S. Justesen</name><name sortKey="Lamberth, K" sort="Lamberth, K" uniqKey="Lamberth K" first="K." last="Lamberth">K. Lamberth</name><name sortKey="Lund, O" sort="Lund, O" uniqKey="Lund O" first="O." last="Lund">O. Lund</name><name sortKey="Lundegaard, C" sort="Lundegaard, C" uniqKey="Lundegaard C" first="C." last="Lundegaard">C. Lundegaard</name><name sortKey="Nielsen, M" sort="Nielsen, M" uniqKey="Nielsen M" first="M." last="Nielsen">M. Nielsen</name><name sortKey="R Der, G" sort="R Der, G" uniqKey="R Der G" first="G." last="R Der">G. R Der</name><name sortKey="Thomadsen, H" sort="Thomadsen, H" uniqKey="Thomadsen H" first="H." last="Thomadsen">H. Thomadsen</name><name sortKey="Worning, P" sort="Worning, P" uniqKey="Worning P" first="P." last="Worning">P. Worning</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005711 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005711 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8A3B5C6659F9727960EFE6E4405375EC6436E8C9
|texte= SARS CTL vaccine candidates; HLA supertype‐, genome‐wide scanning and biochemical validation
}}
| This area was generated with Dilib version V0.6.33. |  |